Gil Granados
About Gil Granados
Gil Granados is the Director of Global Labeling at Bristol Myers Squibb and Celgene, with over 20 years of experience in Global Labeling and Regulatory Affairs.
Title and Current Roles
Gil Granados holds the title of Director, Global Labeling. He is currently working at both Bristol Myers Squibb in New Jersey and Celgene in the same capacity. He began his role at Bristol Myers Squibb in November 2019, bringing his expertise in global labeling to the company.
Previous Experience at Amgen
From 2014 to 2017, Gil Granados served as Director, Global Labeling at Amgen. During his three-year tenure, he focused on global labeling strategies and regulatory affairs, contributing to various projects within the company.
Professional Background at Sanofi Pasteur
Gil Granados worked at Sanofi Pasteur in multiple roles, starting as Regulatory Labeling from 2004 to 2008, and then advancing to Director, Regulatory Labeling from 2008 to 2014. In his six years as a director, he led regulatory labeling projects and contributed to the company's regulatory compliance.
Education and Credentials
Gil Granados earned his Bachelor of Science (B.S.) degree from Fordham University and his Master of Science (M.S.) in Biochemistry from New York University. His academic background provided a strong foundation for his career in global labeling and regulatory affairs.
Expertise in Global Labeling and Regulatory Affairs
With over 20 years of experience, Gil Granados is an expert in global labeling and regulatory affairs. His expertise spans development and marketed products for drugs, biologics, combination products, and biosimilars. He specializes in packaging and supply chain management, as well as end-to-end labeling (E2E) from trigger to implementation.
Therapeutic Areas of Focus
Gil Granados has extensive experience in various therapeutic areas, including CAR-T biologics, hematology, oncology, and inflammation. His work in these fields has enabled him to contribute significantly to the development and regulatory approval of products within these therapeutic areas.